Portfolio company
TargeGen
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule kinase inhibitors to treat blood disorders and inflammatory diseases for patients with unmet medical needs.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Imago BioSciences
This biopharmaceutical company develops small molecule inhibitors to treat patients with myeloproliferative neoplasms and other bone marrow diseases.
Pharmacyclics
This company develops small-molecule medicines for patients with cancer and immune-mediated diseases.
Kinnate Biopharma
The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.
Crossfire Oncology
This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.
TargED
This biotechnology company develops targeted biological drugs that deliver enzymes to blood clots to treat patients with various forms of thrombosis.
Veralox
This biotechnology company develops small-molecule therapeutics to treat inflammatory hematologic diseases and type 1 diabetes for patients with unmet medical needs.
Type6
Type6 develops kinase inhibitors that stabilise proteins in inactive states to treat cancers for the pharmaceutical and drug development industries.
Ribon Therapeutics
This biotechnology company develops small molecule inhibitors targeting stress support pathways for patients with cancer and inflammatory diseases.